MET Maintained by UBS -- Price Target Raised to $110
UBS maintained a 'Buy' rating on MetLife (MET) and raised its price target to $110 from $105. MetLife's stock is currently trading at $98.61, which is 4.3% above its GF Value™ of $94.58. The company has a GF Score™ of 76/100, indicating solid performance in profitability and momentum. MetLife operates in various segments, including insurance and investment management, with a market capitalization of approximately $62.66 billion.
How this was made
The 30-second read
Why it matters
The price‑target raise could attract short‑term buying interest, but the stock remains slightly overvalued per GF metrics.
Market read
Analyst upgrade may nudge MET higher; broader market impact is modest.
What to watch
Potential headwinds from interest‑rate volatility and underwriting losses are not addressed in the rating note.
Background
MetLife is a large U.S. insurer with a market cap of ~$62 bn. Recent analyst coverage has been broadly positive.
Ticker impact
UBS analyst Michael Ward maintained a "Buy" rating on MetLife and raised the price target to $110 from $105.
likely upward pressure as investors price in the higher target
Target raise reflects confidence in earnings and growth; no immediate catalyst beyond the rating update.
Market effects
May boost sentiment for the insurance sector as analysts show confidence in MetLife's performance.
US financial services market could see modest uplift from the rating upgrade.
Limited to investors tracking US insurers; no broader macro impact.
Counterpoint
The higher target may be premature given MetLife's elevated P/E relative to its 5‑year median.
Key entities
- companyMetLife
U.S. insurer (ticker MET) receiving a raised price target.
- analyst_firmUBS
Provided the rating update and new target.
